DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20203537

Parameters affecting the period for being euthyroid in newly-diagnosed Graves’ disease treated with antithyroid agent

Iskender Ekinci, Hande Peynirci

Abstract


Background: There are limited data about the factors affecting the response time to medical treatment in Graves’ disease (GD) although many studies examined the predictors of the relapse after drug withdrawal. The aim of the current study was to evaluate the time for becoming euthyroid under antithyroid drug (ATD) therapy and the parameters influencing this period in patients diagnosed as GD.

Methods: Patients with newly-diagnosed GD and decided to treat with ATD initially between March 2017 and September 2018 were retrieved retrospectively. Sociodemographic features as well as laboratory parameters like thyroid function tests and thyroid-stimulating hormone-receptor antibody (TRab) at the time of diagnosis were recorded.

Results: Out of 41 patients, 63.4% (n=26) were female. The mean age was 36.1±11.7 years and 43.9% (n=18) of them were smoking. The time between the initiation of treatment and the duration of becoming euthyroid was 2.4±1.8 months. No significant difference was noted between age, gender, and smoking status and the time to become euthyroid under ATD treatment. This period was significantly positively correlated with levels of free triiodothyronine, free thyroxine, and negatively correlated with thyroid-stimulating hormone. Response to ATD therapy was higher in patients with pre-treatment TRab levels <10 IU/l than TRab ≥10 IU/l (p=0.011).

Conclusions: Pretreatment thyroid function tests and TRab levels may be taken into consideration before deciding treatment in patients with newly diagnosed GD. It would be useful to design more comprehensive studies so that this proposal can find a response in clinical practice.


Keywords


Euthyroidism, Free thyroxine, Free triiodothyronine, Graves’ disease, Thyroid-stimulating hormone, Thyroid-stimulating hormone-receptor antibody

Full Text:

PDF

References


De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388:906-18.

Wiersinga WM. Graves' disease: can it be cured? Endocrinol Metab. 2019;34:29-38.

Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol. 1977;7:481-93.

Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2000;85:1038‐42.

Wiersinga WM. Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. Endocrinol Metab. 2016;31:213-22.

Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan and the United States. Thyroid. 1991;1:129-35.

Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab. 2012;97:4549-58.

Choi HS, Yoo WS. Free thyroxine, anti-thyroid stimulating hormone receptor antibody titers, and absence of goiter were associated with responsiveness to methimazole in patients with new onset Graves’ disease. Endocrinol Metab. 2017;32:281‐7.

Magri F, Zerbini F, Gaiti M, Capelli V, Ragni A, Rotondi M, et al. Gender influences the clinical presentation and long-term outcome of Graves’ disease. Endocr Pract. 2016;22:1336-42.

Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, et al. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves’ disease: a 120 months prospective study. Endocr J. 2007;54:713-20.

Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369-75.

Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of Graves’ disease- real life data. Endocrine. 2017;56:568‐78.

Bolaños F, González-Ortiz M, Durón H, Sánchez C. Remission of Graves' hyperthyroidism treated with methimazole. Rev Invest Clin. 2002;54:307-10.

Wiersinga WM. Smoking and thyroid. Clin Endocrinol. 2013;79:145-51.

Liu L, Lu H, Liu Y, Liu C, Xun C. Predicting relapse of Graves’ disease following treatment with antithyroid drugs. Exp Ther Med. 2016;11:1453-58.

Mohlin E, Nyström HF, Eliasson M. Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000-2010. Eur J Endocrinol. 2014;170:419-27.

Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves’ disease. Thyroid. 2005;15:1047‐54.

Glinoer D, de Nayer P, Bex M, Belgian Collaborative Study Group on Graves’ disease. Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol. 2001;144:475-83.

Benker G, Vitti P, Kahaly G, Raue F, Tegler L, Hirche H, et al. Response to methimazole in Graves’ disease. The European Multicenter Study Group. Clin Endocrinol. 1995;43:257-63.

Park S, Song E, Oh HS, Kim M, Jeon MJ, Kim WG, et al. When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued? Endocrine. 2019;65:348-56.

Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, et al. Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest. 2018;41:1425-32.

Struja T, Kaeslin M, Boesiger F, Jutzi R, Imahorn N, Kutz A, et al. External validation of the GREAT score to predict relapse risk in Graves’ disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol. 2017;176:413-9.

Shi H, Sheng R, Hu Y, Liu X, Jiang L, Wang Z, et al. Risk factors for the relapse of Graves’ disease treated with antithyroid drugs: a systematic review and meta-analysis. Clin Ther. 2020;42:662-75.e4.

Liu X, Shi B, Li H. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment. Ann Endocrinol. 2015;76:679-83.

Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol. 2002;147:583-9.

Tun NN, Beckett G, Zammitt NN, Strachan MW, Seckl JR, Gibb FW. Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves' disease relapse. Thyroid. 2016;26:1004-9.

Karmisholt J, Andersen SL, Bulow-Pedersen I, Carlé A, Krejbjerg A, Nygaard B. Predictors of initial and sustained remission in patients treated with antithyroid drugs for Graves’ hyperthyroidism: the RISG study. J Thyroid Res. 2019;2019:5945178.

Gemma R, Nakamura H, Mori T, Andoh S, Suzuki Y, Yoshimi T. The change in 123I-uptake between 3- and 24-hours is useful in predicting early response to methimazole in patients with Graves' disease. Endocr J. 1996;43:61-6.

Takaichi Y, Tamai H, Honda K, Nagai K, Kuma K, Nakagawa T. The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves’ disease treated with antithyroidal drugs. J Clin Endocrinol Metab. 1989;68:1097-100.